Objective To discuss the clinical therapy effect and safety degree of type Ⅱ diabetic nephropathy by the intervention treatment of Sanqi Panaxnotoginseng Injection combined with Gliclazide and Melbine. Methods From September 2011 to December 2014, in Department of Endocrinology, the Fourth Affiliated Hospital of Guangxi Medical University, 80 patients with diabetic nephropathy (DN) were selected as research subjects, all of them belonged to the newest diagnosis standard of WHO of type Ⅱ diabetes patients and they were divided into observation group and con-trol group according to random number table, with 40 patients in each group. The patients of two groups were educated with basic knowledge of diabetes before medical treatment, patients in control group were treated with Gliclazide sus-tained-release tablets by oral administration, 60 mg/time, 3 times/d and metformin hydrochloride enteric coated tablets by oral administration, 0.5 g/time, 3 times/d; patients in observation group were treated with injection of Sanqi Panaxnotoginseng Injection as supplement, 10 mL/time, twice/d. The therapy period involved three weeks. Before and after the therapy, all of the blood flow indexes, coagulation indexes, excretion of urinary protein and adverse reaction were recorded. Results After the therapy, patients in observation group had significant improvements in low shear blood viscosity, plasma viscosity and red cell assembling index, the differences were statistically significant (P< 0.05); the coagulation indexes of patients in observation group recovered to within the range of reference value and displayed great improvement compared with that of control group, the differences were statistically significant (P< 0.05); the uri-nary albumin excretion rate of patients in observation group were lower compared with that of control group, the differ-ences were statistically significant (P< 0.05), while the testing result of serum creatinine of two groups, the differences was not statistically significant (P>0.05). During the three-week therapy period patients from both groups showed no adverse effect. Conclusion There is good therapy effect and high safety degree of intervention treating type Ⅱ diabetic nephropathy with Sanqi Panaxnotoginseng Injection, which deserves further development.%目的：探讨血塞通注射液联合格列齐特、二甲双胍治疗2型糖尿病肾病的临床效果和安全性。方法选择2011年9月~2014年12月在广西医科大学第四附属医院内分泌科接受治疗的80例糖尿病肾病患者作为研究对象,根据随机数字表法分为观察组和对照组,每组各40例。两组患者进行药物治疗前均进行糖尿病基本知识教育,其中对照组患者口服格列齐特缓释片,每次60 mg,3次/d,口服二甲双胍肠溶片,每次0.5 g,3次/d；观察组在此基础上加用血塞通注射液,每次10 mL,2次/d。疗程为3周,治疗前后检查并记录各项血液流变学指标、凝血指标、微量尿蛋白的排泄量以及不良反应发生情况。结果治疗后,观察组患者在全血低切黏度、血浆黏度和红细胞聚集指数3项指标上较对照组有显著性的改善,差异有统计学意义(P<0.05)；观察组各项凝血指标均恢复至参考值范围之内,且与对照组比较均有明显改善,差异有统计学意义(P<0.05)；观察组患者微量尿白蛋白排泄量显著降低,差异有统计学意义(P <0.05),而两组间血清肌酐的检测结果差异无统计学意义(P >0.05)。3周疗程内两组患者均未发现任何不良反应。结论血塞通注射液干预格列齐特、二甲双胍治疗2型糖尿病肾病,临床疗效好,安全性高,值得临床上进一步推广。
展开▼
